7-Methyl-7,8-dihydroisoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 7-Methyl-7,8-dihydroisoquinoline
• 英文别名: 7-methyl-7,8-dihydroisoquinoline
• 化学式: C₁₀H₁₁N
• 分子量: 145.2
• InChiKey: OXUVIVKZXOEGSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• 9-membered fused ring derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10233156B2

  公开（公告）日：2019-03-19

  The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; —L1— is —O—(CR6R7)m— or the like; —L2— is —O—(CR6R7)n— or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.

  本发明的目的是提供具有 ACC2 选择性抑制活性的新型化合物。此外，本发明还提供了一种包含该化合物的药物组合物。 式的化合物： 或其药学上可接受的盐、 其中，R1 是由式表示的取代或未取代的融合芳香杂环基： 其中 环 B 是 5 元环，环 C 是 6 元环； 环 A 是取代或未取代的非芳香族碳环或类似物； -L1-是-O-(CR6R7)m-或类似物； -L2-是-O-(CR6R7)n-或类似物； 每个 R6 独立地为氢或类似物 每个 R7 独立地为氢或类似物； 每个 m 独立地为 0、1、2 或 3 的整数 每个 n 独立地为 1、2 或 3 的整数； R2 是取代或未取代的烷基； R3 是氢或取代或未取代的烷基； R4 是取代或未取代的烷基羰基或类似物。
• 9-MEMBERED FUSED RING DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：US20180079727A1

  公开（公告）日：2018-03-22

  The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R 1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L 1 - is —O—(CR 6 R 7 )m- or the like; -L 2 - is —O—(CR 6 R 7 )n- or the like; each R 6 is independently hydrogen or the like; each R 7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R 2 is substituted or unsubstituted alkyl; R 3 is hydrogen or substituted or unsubstituted alkyl; R 4 is substituted or unsubstituted alkylcarbonyl or the like.